SMAD family member 5Genealiases: DWFC · JV5-1 · MADH5
Q-omics provides the consensus-scored SMAD5 profile across patient tissues and cancer cell-line models. SMAD5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SMAD5 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, SMAD5 RNA expression shows 20,825 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, THCA, and KIRP as cancer lineages where SMAD5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMAD5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMAD5 survival associations across molecular data types. SMAD5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMAD5 RNA expression–survival associations across cancer types. High SMAD5 expression shows unfavorable associations in HNSC, STAD, KICH, CESC and ESCA, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SMAD5 RNA expression.
This table summarizes SMAD5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SMAD5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMAD5 shows lower tumor expression in THCA and UCEC and higher tumor expression in LIHC, COAD, HNSC and CHOL. The THCA box plot shows higher SMAD5 RNA expression in normal versus tumor tissue (log2 FC = −0.621, t-test p < 0.001).
This table shows molecular features associated with SMAD5 in patient tissues and cancer cell lines. In patient samples, SMAD5 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, SMAD5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and CNS.
